ObjectiveAs the first laboratory to offer massively parallel sequencing-based noninvasive prenatal testing (NIPT) for fetal aneuploidies, Sequenom Laboratories has been able to collect the largest clinical population experience data to date, including >100,000 clinical samples from all 50 U.S. states and 13 other countries. The objective of this study is to give a robust clinical picture of the current laboratory performance of the MaterniT21 PLUS LDT.
展开▼
机译:目标作为首个为胎儿非整倍性提供大规模平行测序的无创产前检测(NIPT)的实验室,Sequenom Laboratories能够收集迄今为止最大的临床人群经验数据,包括来自美国50个州和其他13个州的100,000多个临床样品国家。这项研究的目的是为MaterniT21 PLUS LDT的当前实验室性能提供可靠的临床图像。
展开▼